Functional genomics and next-generation sequencing (NGS)

Next-generation sequencing (NGS) services

Our experienced sequencing team offers integrated sequencing services for client projects, from sample to result. We utilise state-of-the-art NGS technology to identify novel targets and analyse the mode-of-action of compounds with unprecedented resolution. Single-cell sequencing is especially effective for measuring exploratory biomarkers in preclinical and clinical studies. Our NGS services are customised to meet your specific needs, including experimental design, professional lab execution, in-house NGS sequencing and tailored bioinformatics analysis — all integrated at our Berlin site. We have extensive experience handling preclinical and clinical (GCP-compliant) samples.

• DNA and RNA isolation services
• Bulk sequencing services:
  • Transcriptome sequencing (RNA-seq)
  • DRUG-seq/high-throughput seq
  • Genome sequencing
  • Exome sequencing
  • Epigenetic profiling
  • ChiP-seq
  • Methylome-seq
  • ATAC-seq
  • Ribo-seq
  • SLAM-seq
  • Amplicon and panel sequencing
  • Barcode-seq for CRISPR screening, AAV and LNP tissue distribution
• 10x Genomics single-cell sequencing
  • scRNA-seq (3′ and 5′ RNA workflows)
  • scATAC-seq
  • T- and B-cell receptor profiling
  • CITE-seq
  • Perturbation-seq (CRISPR ko or CRISPRi combined with single-cell sequencing)
  • Custom scAmplicon-seq.

High-throughput transcriptomics with DRUG-seq

As part of Nuvisan’s functional genomics and NGS capabilities, DRUG-seq enables transcriptomic compound profiling at scale in 384- and 1536-well formats. The workflows are designed for the efficient screening of large compound libraries, generating robust, high-quality and AI-ready transcriptomic datasets that can be integrated with complementary discovery approaches.

Our platform provides detection rates of more than 10,000 genes per well in 1536-well format and more than 15,000 genes per well in 384-well format. This supports a broad assessment of compound-induced transcriptional responses across screening campaigns.

Our DRUG-seq capabilities can be combined with genome-wide CRISPR screening to support applications such as compound target identification and pathway analysis. They also complement morphological profiling data from cell painting, helping to build a multi-dimensional view of compound activity and supporting data-driven decision-making in your discovery programs. 

Bioinformatics and omics data analysis

We offer tailored in-house analysis of proprietary, experimental and publicly available biological data, delivered by our team of bioinformaticians, computational biologists, data scientists and pharmacology experts. Our state-of-the-art data science methods, including data mining, integration, multivariate statistics, data visualisation and machine learning, help us achieve consistent scientific excellence.

Our goal is to generate meaningful insights by interpreting results within biological and pharmacological contexts. In silico evaluation of targets and indications helps predict and rank  targets implicated in disease. These targets can then be validated using our extensive portfolio of in vitro assays. 

Selected services include: 

• In silico target and indication space evaluation
• Analysis of cellular screens (CRISPR, RNAi, MITE-seq)
• Next-generation bulk and single-cell sequencing data analysis as a stand-alone or fully integrated service
• High-content cellular assay analysis: fully customisable microscopy image analysis at single-cell resolution, single-cell CRISPR screening
• Large-scale mass-spectrometry data analysis.